Galapagos (GLPG) Competitors $31.92 +0.16 (+0.50%) Closing price 04:00 PM EasternExtended Trading$31.98 +0.06 (+0.19%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLPG vs. BPMC, ROIV, GRFS, LEGN, RVMD, RYTM, RNA, NUVL, AXSM, and CRSPShould you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Galapagos vs. Its Competitors Blueprint Medicines Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Axsome Therapeutics CRISPR Therapeutics Galapagos (NASDAQ:GLPG) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations. Is GLPG or BPMC more profitable? Galapagos has a net margin of 0.00% compared to Blueprint Medicines' net margin of -27.70%. Galapagos' return on equity of 0.00% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets GalapagosN/A N/A N/A Blueprint Medicines -27.70%-64.60%-17.22% Does the media refer more to GLPG or BPMC? In the previous week, Blueprint Medicines had 1 more articles in the media than Galapagos. MarketBeat recorded 1 mentions for Blueprint Medicines and 0 mentions for Galapagos. Galapagos' average media sentiment score of 0.99 beat Blueprint Medicines' score of 0.00 indicating that Galapagos is being referred to more favorably in the media. Company Overall Sentiment Galapagos Positive Blueprint Medicines Neutral Do insiders & institutionals hold more shares of GLPG or BPMC? 32.5% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate GLPG or BPMC? Galapagos presently has a consensus price target of $25.33, suggesting a potential downside of 20.63%. Blueprint Medicines has a consensus price target of $130.00, suggesting a potential upside of 0.42%. Given Blueprint Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Blueprint Medicines is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galapagos 5 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.38Blueprint Medicines 0 Sell rating(s) 16 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11 Which has more volatility & risk, GLPG or BPMC? Galapagos has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Which has higher valuation and earnings, GLPG or BPMC? Galapagos has higher earnings, but lower revenue than Blueprint Medicines. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalapagos$298.31MN/A$80.16MN/AN/ABlueprint Medicines$562.12M14.87-$67.09M-$2.47-52.41 SummaryBlueprint Medicines beats Galapagos on 7 of the 13 factors compared between the two stocks. Get Galapagos News Delivered to You Automatically Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLPG vs. The Competition Export to ExcelMetricGalapagosMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$3.11B$5.74B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E RatioN/A20.4030.4525.16Price / SalesN/A238.54392.5887.64Price / Cash44.2142.3737.0358.50Price / Book0.677.918.956.21Net Income$80.16M-$54.72M$3.26B$265.38M7 Day Performance0.41%1.63%1.06%-1.13%1 Month Performance-0.68%5.86%4.31%-0.71%1 Year Performance26.57%8.70%28.40%18.89% Galapagos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLPGGalapagos0.3485 of 5 stars$31.92+0.5%$25.33-20.6%+27.9%$0.00$298.31M0.001,310BPMCBlueprint Medicines0.4895 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.2878 of 5 stars$11.81-0.3%$16.50+39.7%+2.1%$8.06B$29.05M-16.87860Positive NewsGRFSGrifols3.5072 of 5 stars$10.58-1.3%$10.30-2.6%+41.2%$7.37B$7.45B9.0423,822Short Interest ↑LEGNLegend Biotech3.866 of 5 stars$37.45-0.1%$72.38+93.3%-37.6%$6.89B$627.24M-42.562,609RVMDRevolution Medicines4.3638 of 5 stars$36.45+0.4%$69.54+90.8%-16.6%$6.79B$11.58M-8.10250Trending NewsAnalyst ForecastAnalyst RevisionRYTMRhythm Pharmaceuticals3.7232 of 5 stars$98.09+0.5%$101.57+3.5%+116.4%$6.48B$130.13M-32.59140News CoverageRNAAvidity Biosciences3.157 of 5 stars$44.48-4.3%$67.00+50.6%-1.2%$5.98B$10.90M-12.49190News CoverageOptions VolumeNUVLNuvalent3.1902 of 5 stars$75.01-1.4%$119.60+59.4%-4.0%$5.48BN/A-15.3140News CoverageAnalyst ForecastInsider TradeAXSMAxsome Therapeutics4.7766 of 5 stars$111.13+1.8%$178.00+60.2%+32.7%$5.45B$385.69M-21.92380CRSPCRISPR Therapeutics3.7617 of 5 stars$57.59-3.6%$71.60+24.3%+8.2%$5.43B$37.31M-10.61460 Related Companies and Tools Related Companies BPMC Competitors ROIV Competitors GRFS Competitors LEGN Competitors RVMD Competitors RYTM Competitors RNA Competitors NUVL Competitors AXSM Competitors CRSP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLPG) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galapagos NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Galapagos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access